Advances in BCMA-CAR-T therapy of multiple myeloma and management after relapse
YAN Sijia
XIAO Yi
Abstract：Multiple myeloma(MM)is a prevalent hematological malignancy.Despite the availability of various therapeutic agents,disease relapse remains inevitable.In recent years,B cell maturation antigen(BCMA)-targeted chimeric antigen receptor T(CAR-T)cell therapy has demonstrated remarkable success in treating relapsed/refractory(R/R)MM,offering new hope for RRMM patients.Currently,four types of BCMA-CAR-T products are available on the global market,and their application in RRMM is becoming increasingly widespread.However,RRMM patients who receive BCMA-CAR-T treatment still exhibit a high relapse rate.Research on maintenance therapy following BCMA-CAR-T treatment is currently limited,and multiple strategies exist for managing post-relapse RRMM after BCMA-CAR-T therapy.
Keywords：multiple myelomaBCMA-CAR-Trelapse
Publication Date：2025-04-10
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 929-935 )